natgillin/translations-raw huggingface dataset:
The phacoemulsification tip of claim 3, wherein the proximal end (114) of the tip includes a conical portion and wherein a length of the conical portion is selected to increase twisting vibrations of the tip during ultrasonic torsional vibrations to provide a greater lateral displacement at the distal end point (106) of the tip. 
Fakoemulzifikacijski vrh prema zahtjevu 3, naznačen time, daje proksimalni kraj (114) od vrha koji uključuje stožasti odsječak i pri čemu je duljina stožastog odsječka odabrana kako bi povećala zavrnute vibracije od vrha za vrijeme ultrazvučnih torzijskih vibracija, u svrhu postizavanja većeg bočnog premještanja na točki distalnog kraja (106) od vrha.
Use of N-(2-aminophenyl)-4-[N-(pyridine-3-yl)methoxycarbonylaminomethyl]benzamide polymorph B for the production of a medicament for the treatment of malignant tumors, auto - immune diseases, dermatological diseases and parasitism. 
Uporaba N-(2-aminofenil)-4-[N-(piridin-3-il)metoksikarbonilaminometil]benzamid polimorfa B, naznačena time da se odnosi na proizvodnju lijeka za liječenje malignih tumora, autoimunih bolesti, kožnih bolesti i parazitizama.
9.Method according to items 1 to 8 whereby said method results in increased specific cellular productivity of said protein of interest in said cell in comparison to a control cell expressing said protein of interest, but whereby said control cell does not have increased expression or activity of a protein having an amino acid sequence comprising a steroidogenic acute regulatory related lipid transfer (START) domain or a derivative or mutant thereof. 
Postupak prema zahtjevima od 1 do 5, naznačen time, da, spomenuti postupak rezultira s povećanjem specifične stanične produktivnosti spomenutog korisnog proteina u spomenutoj stanici, u usporedbi sa kontrolnom stanicom za ekspresiju spomenutog korisnog proteina, ali pri čemu spomenuta kontrolna stanica nema povećanje ekspresije niti djelovanja proteina s amino-kiselinskom sekvencom, koja sadrži ceramidni prijenosni protein CERT ili njegov derivat ili njegov mutant.
a carbonyl scavenger compound selected from the group consisting of: free acid forms, salts, and carboxylic acid esters derivatives of a compound of formula (II) 
6) spoj za čišćenje karbonila odabran od slobodnih oblika kiseline, soli, derivata estera karboksilne kiseline spoja prema formuli (II)
The method of claim 13, wherein the diluent is selected from the group consisting of starch; lactose; sucrose; sucrose based diluents such as confectioner's sugar, sucrose plus 7 to 10 weight percent invert sugar, sucrose plus about 3 weight percent modified dextrins; sucrose plus invert sugar, about 4 weight percent invert sugar, 0.1 to 0.2 weight percent cornstarch and magnesium stearate; dextrose; inositol; mannitol; sorbitol; microcrystalline cellulose; dicalcium phosphate; calcium sulfate dihydrate; and calcium lactate trihydrate. 
Farmaceutska dozna formulacija prema patentnom zahtjevu 5, naznačena time što je diluent izabran iz grupe koju čine škrob; laktoza; saharoza; diluenti na bazi saharoze kao što je konditorski šećer, saharoza sa dodatkom 7 do 10 masenih postotaka invertnog šećera, saharoza sa dodatkom oko 3 masena postotka modificiranih dekstrina; saharoza sa dodatkom invertnog šećera, oko 4 masena postotka invertnog šećera, 0.1 do 0.2 masena postotka kukuruznog škroba i magnezij stearata; dekstroza; inozit; manitol; sorbitol; mikrokristalna celuloza; dikalcij fosfat; kalcij sulfat dihidrat; i kalcij laktat trihidrat.
The vaccine of claim 6, wherein a) the bacterial toxoid is diphtheria toxoid, or a derivative thereof; or b) the virus-like particle is HBsAg, HBcAg, E. coli bacteriophage QB, Norwalk virus or influenza HA. 
Cjepivo u skladu s patentnim zahtjevom 5, naznačeno time što bakterijski toksoid je difterijski toksoid, ili njegov derivat; ili virusu slična čestica je HBsAg, HBcAg, E. coli bakteriofag QB, virus Norwalk ili influenca HA.
The composition for use according to claim 1, wherein the therapeutically effective amount of crenolanib or pharmaceutically acceptable salt thereof is from 50 to 500 mg per day, 100 to 450 mg per day, 200 to 400 mg per day, 300 to 500 mg per day, 350 to 500 mg per day, or 400 to 500 mg per day. 
Pripravak namijenjen uporabi u skladu s patentnim zahtjevom 1, pri čemu terapijski djelotvorna količina crenolaniba ili njegove farmaceutski prihvatljive soli iznosi od 50 do 500 mg dnevno, od 100 do 450 mg dnevno, od 200 do 400 mg dnevno, od 300 do 500 mg dnevno, od 350 do 500 mg dnevno ili od 400 do 500 mg dnevno.
The method of claim 26, wherein nalmefene is administered as the hydrochloride dihydrate. 
Nalmefen za uporabu prema zahtjevu 9, gdje se nalmefen primjenjuje u obliku hidroklorid dihidrata.
A pharmaceutical composition of claim 16, wherein said compound is a compound of claim 5, 8, 9, 10, 11, 12, 13, 14, or 15. 
Farmaceutski sastav zahtjeva 16, naznačen time, da je spomenuti spoj onaj iz zahtjeva 5, 8, 9, 10, 11, 12,13, 14,ili
Het1 is selected from the group comprising and 
Het' je odabran iz skupine koja sadrži i
The salt form of claim 4, wherein the a-6-mPEG6-O-hydroxycodone phosphate salt is a monophosphate salt. 
Oblik soli iz patentnog zahtjeva 4, naznačen time, što je a-6-mPEG6-O-hidroksikodon fosfatna sol monofosfatna sol.
In a further embodiment, the present invention also relates to use of a compound of formula I for the preparation of a medicament for the treatment of general anxiety disorder. 
U daljnjoj verziji, ovaj izum sa odnosi i na uporabu spoja formule I za pripravu lijeka za liječenje poremećaja opće tjeskobe.
A composition comprising the target binding member of claim 1 and a pharmaceutically acceptable carrier, which composition is optionally in the form of a lyophilized powder. 
Sastav, naznačen time, da obuhvaća ciljani vezni element prema zahtjevu 1 1 farmaceutski prihvatljiv nosač, pri čemu je taj sastav po želji u obliku liofiliziranog praška.
wherein one of the carbons in said cycloalkyls, independently, or cycloheteroalkyl may form a carbonyl group, and wherein said phenyl, thienyl, or pyridinyl is optionally substituted with halo or a carbamoyl group; 
O gdje jedan od ugljika u navedenim cikloalkilima, neovisno, ili u cikloheteroalkilu, može tvoriti karbonilnu skupinu, te gdje je navedeni fenil, tienil ili piridinil izborno supstituiran s halogenom ili karbamoilnom skupinom;
The rotary machine according to claim 1, characterized in that the housing (5c') is made up by two substantially C-formed housing parts (5e, 5f), which parts together form a housing having axially extending partition surfaces and are adapted to be mountable over a reel structure configuration made in one piece. 
Rotacijski motor prema patentnom zahtjevu 1, naznačen time da je kućište (5c') sastavljeno od dva dijela kućišta koja su u suštini u C-obliku (5e, 51), koji dijelovi zajedno tvore kućište s aksijalno proširenim pregradnim površinama 1 prilagođeno je da se može montirati preko konfiguracije konstrukcije valjka iz jednog komada.
A method of encapsulating at least one agent in silk fibroin, comprising: (i) contacting an aqueous silk fibroin solution with an ultrasonication treatment for a period of about 5 seconds to about 60 seconds to initiate gelation, wherein the power output of ultrasonication ranges from about 10% to about 50% amplitude, and wherein the silk fibroin is selected from the group consisting of silk produced by silkworms, silk produced by spiders and variants thereof; and 
Postupak kapsuliranja barem jednog sredstva u fibroin svile, obuhvaća: dovođenje u doticaj otopine fibroina svile s obradom pomoću ultrazvukom kroz vrijeme od oko 5 sekundi do oko 60 sekundi radi započinjanja geliranja; i uvođenje sredst(a)va u otopinu fibroina svile prije nego što dođe do značajnijeg geliranja u otopini fibroina svile; kako bi se dobilo sredstvo kapsulirano u fibroinu svile.
reacting a chiral alcohol of Formula VIII, an imine of Formula IX and a silyl protecting agent, then condensing the silyl-protected compounds to obtain a B-(substituted-amino)amide of Formula XII, wherein X is -O-, -S- or -N(C1-C6 alkyl); Y is =O or =S; and R1 is alkyl, aryl or alkoxycarbonyl, and wherein Prot is a silyl protecting group: prior to cyclizing the B -(substituted-amino)amide of Formula XII. 
reakcije kiralnog alkohola Formule VIII, imina Formule IX i slilnog zaštitnog agensa, zatim kondenzacije silil-zaštićenih spojeva za dobivanje B-(supstituiranog-amino)amida Formule XII, gdje je X predstavljen s –O-, -S- ili –N(C1-C6 alkil); Y je =O ili =S; i R1 je alkil, aril ili alkoksikarbonil, i gdje je Prot sililna zaštitna skupina: [image] prije cikliziranja B-(supstituiranog-amino)amida Formule XII.
A tabletting tool with top punch, bottom punch and die for tablets with a diameter of 7 mm was heated to 80° C. in a heating cabinet. 150 mg portions of the powder mixture were pressed with the heated tool, wherein pressure was maintained for at least 15 seconds by clamping the tabletting tool in a vice. 
Alat za tabletiranje s gornjim kalupom, donjim kalupom i matricom za tablete promjerom od 7 mm zagrijan je u komori za zagrijavanje na 80*C. Pomoću zagrijanog alata prešano je uvijek 150 mg praškaste smjese, kod čega je pritisak prešanja održavan najmanje 15 s, pritezanjem alata za tabletiranje u škripcu.
sucrose in an amount of from 5% to 10% w/v; and 
(iv) saharozu u količini od 5 % do 10 % w/vy;1
The process of clause 1, wherein at least about 20 moles of the boron "ate" complex of formula (II) are provided in step (a). 
Postupak prema patentnom zahtjevu 1, gdje je najmanje 20 mola, najmanje 50 mola ili najmanje 100 mola kompleksa borata formule (77) osigurano u koraku (a).
The compound according to claim 1, having the formula VI: or a tautomer, enantiomer or salt thereof, wherein: 
HR P20170404 T1 (VI) ili njegov tautomer, enantiomer ili sol, naznačen time što:
The method of claim 9, wherein the compound is administered orally. The method of claim 9, wherein the disorder is amyotrophic lateral sclerosis. 
poremećaj je traumatska ozljeda mozga; ili poremećaj je odabran od multiple skleroze, lupusa i amiotrofne lateralne skleroze.
a control section that transmits the response signal to the base station apparatus, wherein: the control section transmits, using a first component carrier, a response signal including error detection results for the data pieces respectively received using the first component carrier and a second component carrier among the plurality of component carriers; and in a first configuration pattern that is set in the first component carrier, at least an uplink communication subframe is set at a timing identical to that of an uplink communication subframe of a second configuration pattern that is set in the second component carrier. 
Uređaj bazna stanica prema zahtjevu 1, naznačen time da pluralitet nosača komponenti nadalje uključuje trećeg nosača komponenti; u trećem obrascu konfiguracije okvira koji je postavljen za trećeg nosača komponenti, postavljen je podokvir uzlazne veze najmanje u vremenu različitom od prvog obrasca konfiguracije okvira za Primarnu Stanicu i u prvom obrascu konfiguracije okvira za Primarnu Stanicu, podokvir uzlazne veze je postavljen u vremenu različitom od trećeg obrasca konfiguracije okvira;
Since they are not hygroscopic and/or have increased thermal stability, these salts can be easily handled and are favourably suitable for manufacturing solid administration forms. 
Buduću da one nisu higroskopne i/ili da imaju povećanu toplinsku postojanost, s tim se solima može lako rukovati i one su izvanredno prikladne za proizvodnju krutih oblika za davanje.
New highly functionalizable Huprine derivatives of formula I: 
PATENTNI ZAHTJEVI Spoj formule I: gdje,
Referring now to Figures 4 to 8, container 10 is fabricated in the following steps: 
Pozivajući se sada na slike 4 do 8, spremnik 10 se proizvodi u skladu s ovim izumom u sljedećim koracima:
Carnauba wax is very particularly preferred. 
Naročito je pogodan Carnauba vosak.
In a further preferred embodiment of the integrated rotary mixer and disperser head according to the invention, said serrations have a generally castellation-like profile. 
Integrirana rotacijska miješalica 1 glava raspršivača (1) prema 9. tvrdnji gdje navedena nazupčenja (26, 27) imaju općenito nazubljeni profil.
A composite composition comprising carbon nanotube networks according to claim 3 or 4, further comprising a polymer. 
Kompozicija kompozitnog materijala koja sadrži mreže ugljikovih nanocijevi u skladu s patentnim zahtjevom 3 ili 4, koja dodatno sadrži polimer.
The composition of claim 3, in aqueous form. 
Sastav prema bilo kojem od prethodnih zahtjeva, naznačen time da je u vodenom obliku.
A method according to any preceding claim wherein the surface material (30) is heated prior to the pressing step. 
Postupak prema bilo kojem od prethodnih zahtjeva, naznačen time, da se površinski materijal (30) zagrijava prije koraka stlačivanja.
Use of a compound having the structure shown in claim 1 or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for treating a disease or disorder selected from multiple myeloma, glioblastoma, and lymphoma. 
Uporaba spoja prema zahtjevu 1, ili njegove farmaceuiski prihvatljive soli, naznačena time, da je za proizvodnju lijeka za liječenje bolesti ili poremećaja povezanih sa nekontroliranim, nenormalnim i/ili neželjenim staničnim djelovanjima.
Exemplary reagents and procedures for these reactions appear hereinafter in the working Example. 
Primjeri reagensa i postupaka za ove reakcije navode se u daljnjem tekstu u radnom Primjeru.
A process according to anyone of the preceding claims, wherein the particle size of the obtained solid urea product by flashing is in the range of from 0.1 µm to 1000 µm, preferably of from 1 µm to 800 µm. 
Postupak sukladno bilo kojem od prethodnih zahtjeva, naznačeno time, da je veličina čestica krutog proizvoda dobivenog brzim sušenjem koji sadrži ureu u rasponu od 0.1 um do 1000 um, poželjno od 1 um do 800 um.
a 3' wing segment consisting of five linked nucleosides; 
’ segment „krila“ koji se sastoji od pet vezanih nukleozida;
Device (7) according to claim 1, characterized in that the disconnection of said support means (10) from said connection element (11) cancels the tension of the cord (8). 
Naprava (7) u skladu s patentnim zahtjevom 1, naznačena time što odvajanje navedenog nosača (10) od navedenog spojnog elementa (11) poništava napetost užeta (5).
The method of claim 8, which uses a trap device for controlling the invertebrate pest, the trap device comprising the bait composition and a housing adapted to receive said bait composition, wherein the housing has at least one opening sized to permit the invertebrate pest to pass through the opening so the invertebrate pest can gain access to said bait composition from a location outside the housing, and wherein the housing is further adapted to be placed in or near a locus of potential or known activity for the invertebrate pest. 
Metoda iz patentnog zahtjeva 8, koja koristi klopku za kontrolu štetnika beskralježnjaka, klopka obuhvaća smjesu u obliku mamca i kućište prilagođeno prihvaćanju navedenog mamca, pri čemu kućište ima barem jedan otvor veličine koja dozvoljava štetnicima beskralježnjacima prolaz kroz otvor tako da štetnici beskralježnjaci mogu pristupiti navedenom mamcu iz smjera izvan kućišta, i gdje je kućište nadalje prilagođeno za smještaj u blizini lokaliteta moguće ili poznate aktivnosti štetnika beskralježnjaka.
The fuel element was wrapped with conventional treated cigarette paper. 
Gorivi element je bio omotan sa konvencionalnim tretiranim cigaret papirom.
One or a plurality of vectors, wherein each vector comprises a nucleic acid molecule of claim 7 . 
Vektor, naznačen time što sadrži molekulu nukleinske kiseline prema patentnom zahtjevu 7.
The compound or salt for use in treatment of claim 1, wherein R3 is selected from the group consisting of: methyl, methoxyethyl, 4-pyridylmethyl, 3-pyridylmethyl, 2-pyridylmethyl, benzyl, N,N-dimethylaminopropyl, 3-methylisoxazol-5-yl-methyl, and 4-methylpiperazin-1-yl-propyl. 
Spoj prema zahtjevu 1, naznačen time da R3 je odabran iz skupine koja sadrži: metil, metoksietil, 4-piridilmetil, 3-piridilmetil, 2-piridilmetil, benzil, N,N-dimetilaminopropil, 3-metilizoksazol-5-il-metil, i 4-metilpiperazin-1-il-propil, ili njihovu farmaceutski prihvatljivu sol.
A process according to claim 17 characterized in that a compound having a configuration according to formula (3-a) or a salt thereof is obtained wherein R1 and R2 are independently, of each other, hydrogen or a nitrogen protecting group and R3 is hydrogen or alkyl. 
Teagira sa sredstvom za otvaranje prstena, kako bi se dobio spoj u skladu sa sljedećom formulom (3) ili njegova sol: ska dd ka pri čemu su R1 1 R2 u gornjim formulama, međusobno neovisno vodikova ili dušikova zaštitna skupina 1 R3 je vodik ili alkil.
The compound of claim 1 wherein the optionally substituted aryl group is phenyl. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što je izborno supstituirana arilna skupina fenil.
A method for arresting the progression of motor deficits in a mammal suffering from Parkinson's disease, comprising administration to the mammal of an effective amount of the compound of claim 1 . 
Uporaba spoja prema zahtjevu 1 naznačena time da je za proizvodnju lijeka za uporabu kod zaustavljanja napredovanja motornih deficita kod sisavca koji pati od Parkinsonove bolesti.
Moreover, it may be advantageous to apply the herbicidal compositions and synergistic herbicidal mixtures according to the invention, jointly or separately, with additional other crop protection agents, for example with pesticides or agents for controlling phytopathogenic fungi or bacteria. 
Pored toga, može biti povoljno primjenjivati herbicidne kompozicije i sinergističke herbicidne smjese prema izumu, zajedno ili odvojeno, sa dodatnim sredstvima za zaštitu kultura, na primjer sa pesticidima ili sredstvima za kontrolu fitopatogenih gljiva ili bakterija.
a cancer that is positive for one, two, or all of PD-L1, CD8, or IFN-Y; 
rak koji je pozitivan na jedno, dvoje ili sve od PD-L1, CD8 ili IFN-Y;
In another embodiment the piercer is arranged asymmetrically with respect to a central axis through the base unit. 
U drugoj izvedbi bušilo je postavljeno asimetrično u odnosu na središnju os kroz osnovnu jedinicu.
The organic extracts were combined and dried over anhydrous magnesium sulphate and after filtration the solvent was removed at reduced pressure to afford a yellow oil (9 g). 
Organski ekstrakti se spoje i suše iznad anhidridnog magnezij sulfata i nakon filtriranja se otapalo ukloni uz smanjeni tlak da bi se dobilo žuto ulje (9 g).
poly siloxanes. The intragastric balloon of claim 1, wherein the sealed container is made from one of the following: 
Intragastrički balon (10) sukladno bilo kojem od prethodnih patentnih zahtjeva, pri čemu se taj zapečaćeni spremnik izrađuje od slijedećeg:
The electronic cigarette of claim 1, wherein the housing is configured to enable a user to inhale the first substance, and the first substance comprises a liquid drug. 
E-cigareta (100) sukladno patentnom zahtjevu 1, naznačena time što je kućište (112) konfigurirana tako da korisniku omogućuje udisanje prve tvari i pri čemu prva tvar sadrži nikotin.
said inner fan (5) comprises an inlet (5a) for sucking air and an outlet (5b) for discharging air, 
- < navedeni unutarnji ventilator (5) ima ulaz (54) za usisavanje zraka i izlaz (5b) za ispuštanje zraka,
A cell according to claim 7, wherein the fungal cell is selected from the group consisting of the genera Aspergillus, Trichoderma / Hypocrea, Fusarium, Disporotrichum, Penicillium, Acremonium, Neurospora, Thermoascus, Myceliophtora, Sporotrichum, Thielavia, Chryosporium, Fusarium, Humicola, Neurospora and Talaromyces. 
Stanica prema zahtjevu 7, naznačena time da je stanica gljive odabrana iz skupine koju čine rod Aspergillus, TrichodermalHypocrea, Fusarium, Disporotrichum, Penicillium, Acremonium, Neurospora, Thermoascus, Myceliophtora, Sporotrichum, Thielavia, Chryosporium, Fusarium, Humicola, Neurospora 1 Talaromyces.
Any of these polymers can be used alone, two or more of these polymers can be applied in the form of separate polymer layers or may be applied in the form of a mixture. 
Bilo koji od tih polimera može se upotrijebiti sam, ili se dva ili više od tih polimera može primijeniti u obliku odvojenih polimernih slojeva, ili ih se može primijeniti u obliku smjese.
The antigen-binding fragment according to claim 12, which is selected from the group consisting of the Fab, Fab', F(ab')2, Fv, single chain Fv, diabody and Immunoglobulin single variable domain fragments. 
Antigenski vežući fragment u skladu s patentnim zahtjevom 12, naznačen time što se bira iz skupine koju čine fragmenti Fab, Fab’, F(ab’)2, Fv, jednolančanog Fv, dijatijela i jedne varijabilne domene imunoglobulina.
The method of any one of claims 1 to 3, further comprising passing the buffer solution of the monomeric platinum pyrophosphate complex through an inline filter comprising a filter medium to remove any undissolved solids to obtain a clear filtrate solution prior to said recrystallizing. 
Postupak prema bilo kojem od zahtjeva 1 do 14, naznačen time da nadalje sadrži propuštanje reakcijske smjese kroz linijsku filter kasetu koja sadrži sredstvo za filtriranje da se dobije bistra otopina filtrata reakcijske smjese prije navedenog taloženja.
is selected from the group consisting of H, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, C1-C3 alkoxy, C1-C3 alkylthio, halo, OH, CN, OCF3, and halo-C1-C3-alkyl, which contains 1 to 5 halogens; and R5 are independently selected from H and C1-C3 alkyl, or R4 and R5 can be taken together with the carbon to which they are attached to form a cyclopropyl ring; is a 5-membered heteroaryl ring containing at least one O, N or S atom; 
je odabran iz grupe koja se sastoji od H, C1-C3 alkila, C1-C3 alkoksi, fluoro, kloro, OCF3, i halo-C1-C2-alkila, koji sadrži 1 do 5 halogena; i R5 su nezavisno odabrani od H i metila; je 5-očlani heteroaril prsten odabran od tiazola, tiadiazola, oksazola, oksadiazola, i triazola;
In the manufacture of these shoes, it is critical to pay attention to the seal of the regions where the insole and the lining connect to the membrane and the sole, in order to avoid even the slightest seepage of water from outside. 
U proizvodnji takve vrste cipele od ključne je važnosti hermetički zabrtviti područja na kojima se unutarnji potplat i podstava spajaju s membranom i potplatom kako bi se izbjeglo i najmanje prodiranje vode izvana.
An antibody or antibody fragment for use as a diagnostic agent according to claim 9, wherein the use is for diagnostic in vivo imaging wherein the use is to detect or image IL-6 expressing tumors or metastases, or is to detect or image IL-6 expressing inflammatory sites. 
Anti-IL-6 protutijelo za uporabu kao dijagnostički agens sukladno patentnom zahtjevu 9, pri čemu je uporaba za dijagnostičke in vivo slikovne tehnike a) za detekciju ili prikazivanje tumora ili metastaza koji izražavaju IL-6, ili b) za detekciju ili prikazivanje upalnih mjesta koja izražavaju II-6.
There was no major difference in the mean tmax for both test and reference formulations. 
Nije bilo velike razlike u srednjem t,ax za oba test 1 referentne pripravke.
The method according to any one of the preceding embodiments, wherein the beverage contains in the range of 3 to 10 g/L organic acid, such as in the range of 4 to 7 g/L lactic acid. The method according to any one of the preceding embodiments, wherein the method comprises an additional step f), wherein step f) comprises adding one or more additional compounds to the starting liquid and/or to the AX-REED liquid and/or to the liquid during the method and/or to the beverage. 
Postupak prema bilo kojem od prethodnih zahtjeva, naznačen time što postupak obuhvaća dodatni korak f), pri čemu korak f) sadrži dodavanje jednog ili više dodatnih spojeva u početnu tekućinu i/ili u tekućinu AX-REED i/ili u tekućinu tijekom postupka i/ili u napitak i/ili postupak nadalje obuhvaća korak g) dodavanje jedne ili više dodatnih tekućina u tekućinu AX-REED, tekućinu CX-REED ili tekućinu REED, te se tako dobiva napitak.